Could a protein derived from vitamin d tame chronic inflammation?

NCT ID NCT06877364

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a protein called GcMAF, which is made from vitamin D-binding protein and is thought to calm the immune system. Researchers gave it to 120 adults with chronic inflammatory conditions like rheumatoid arthritis or cystitis that didn't improve with standard treatments. The goal was to check if it's safe and if it can reduce inflammation, measured by blood markers and disease activity scores.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GcMAF (a protein derived from vitamin D-binding protein that activates immune cells)
What this could lead to
If successful, this could point toward a new treatment option for people with chronic inflammatory diseases who haven't responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not confirm effectiveness or safety in larger populations. The treatment is experimental and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC CYSTITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Center For New Medical Technologies

    Novosibirsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.